金吾财讯 | 辉瑞(PFE)披露 2026 年一季度经营财报，整体盈利与营收均大幅跑赢市场预期。公司当季非 GAAP 每股收益录得 0.75 美元，较预期高出 0.03 美元；营收达 145 亿美元，同比上涨 5.7%，较预估多出 7 亿美元，盈利端表现稳健。
剥离新冠疫苗与新冠口服药相关收入后，辉瑞核心主业经营性营收仍实现 7% 的同比增长，已上市及并购整合产品线内生营收增速更是高达 22%，显示非新冠创新药及并购资产成为增长主力。
财报同时披露，一季度摊薄每股收益 0.47 美元，调整后为 0.75 美元。辉瑞并未调整 2026 年全年业绩预期，维持营收 595 亿 —625 亿美元、调整后每股收益 2.80—3.00 美元的区间，与市场中枢预期基本贴合。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.